Mass General Hospital to Pilot AstraZeneca Disease Management Platform
Pharmaceutical company AstraZeneca has entered into a collaboration deal with Massachusetts General Hospital (MGH) to create and clinically validate digital health solutions for the management of chronic illness outside of a clinical setting.
The collaboration is being led by the MGH Center for Innovation in Digital Healthcare (CIDH) and will use AstraZeneca’s new AMAZE disease management platform in studies for heart failure and asthma management. These first two studies will pilot AMAZE in a real-world setting with the goals of improving patient engagement, care-team communication and clinical outcomes while reducing healthcare costs.
Through remote monitoring, AMAZE identifies at-risk patients and delivers insights to the clinical care team at the point of care to improve the management of complex patient populations. The digital platform, including a patient app and clinician dashboard, is intended to speed up evidence-based clinical practice with the aim of continuously improving the standard of patient care and healthcare efficiency.
“This extraordinary level of collaboration between an academic medical center and a pharmaceutical company opens a pathway to innovative digital health solutions that place the patient at the center of care,” said Peter Slavin, M.D., president of Massachusetts General Hospital, in a statement. “By embracing the tension of different perspectives and expertise, we can move faster and more efficiently while maintaining the highest levels of scientific rigor and clinical excellence. While there is no precedent for this type of deep relationship, we hope this alliance will serve as a model for future collaboration between pharma and healthcare providers.”
Following the conclusion of the heart failure and asthma studies, AstraZeneca and Massachusetts General Hospital plan to expand the use of AMAZE across multiple chronic disease areas, reaching patients throughout the Mass General Brigham system, and beyond.
